期刊
FUTURE ONCOLOGY
卷 15, 期 6, 页码 591-599出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0546
关键词
androgen signaling inhibitor; apalutamide; castration-resistant prostate cancer; nonmetastatic; prostate cancer
类别
资金
- NIA NIH HHS [T32 AG000212] Funding Source: Medline
High-risk nonmetastatic castration-resistant prostate cancer is a lethal disease that previously lacked clear treatment options. Progression to bone metastases is associated with significant morbidity and high cost. Apalutamide, an androgen receptor inhibitor, has substantial clinical response in nonmetastatic castration-resistant prostate cancer. Apalutamide + androgen deprivation therapy is well tolerated and improves metastasis-free survival, progression-free survival and time to symptomatic progression, and is associated with a favorable trend of improved overall survival. Future research is needed to elucidate mechanisms of resistance to treatment with androgen signaling inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据